teaser
A study of patients with mixed dyslipidemia and type 2 diabetes has found that a combination of two drugs worked to reduce levels of cholesterol and triglycerides in a significant number of cases.
The phase III study showed that the use of Abbott’s investigational TriLipix (ABT-335) in combination with AstraZeneca’s Crestor (rosuvastatin calcium) demonstrated similar improvements in LDL “bad” cholesterol, HDL “good” cholesterol and triglycerides compared to the overall study population.
Abbott evaluated the efficacy and safety of the combination in a study of more than 1,400 patients with mixed dyslipidemia. TriLipix in combination with rosuvastatin significantly improved HDL and triglycerides compared to rosuvastatin alone, and significantly improved LDL compared to TriLipix alone.
A sub-group of 276 patients were identified as having type 2 diabetes and data from this sub-group demonstrated that the effect of TriLipix in combination with rosuvastatin was similar to that seen in the overall study population.
Dyslipidemia affects millions of people living with diabetes. These patients often have mixed dyslipidemia, a complex combination of lipid problems commonly characterised by high triglycerides, low HDL and moderately high LDL.
“New treatment options are critical given that a substantial number of patients are not achieving treatment goals for their three key lipids,” said Eugene Sun, vice president of Global Pharmaceutical Clinical Development at Abbott.
Copyright © PA Business 2008
